Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Methionine enkephalin - Biostax

Drug Profile

Methionine enkephalin - Biostax

Alternative Names: CYTO-401; INNO-105; IRT-101; IRT-102; MENK; Menkophian; Met-enkephalin; OGF; Opioid growth factor; Proenkephalin; STAT 400; STAT-401

Latest Information Update: 25 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nonindustrial source
  • Developer Biostax; Hubei Qianjiang Pharmaceutical; Penn State College of Medicine; Statera BioPharma
  • Class Antineoplastics; Antivirals; Enkephalins; Essential amino acids; Opioid peptides; Small molecules
  • Mechanism of Action Immunostimulants; Opioid growth factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II HIV infections; Liver cancer; Ovarian cancer; Pancreatic cancer
  • No development reported Solid tumours
  • Discontinued COVID 2019 infections; Influenza A virus H1N1 subtype; Influenza virus infections; Thyroid cancer

Most Recent Events

  • 20 Apr 2023 Statera Biopharma amends royalty-bearing license agreement with Biostax for the rights to methionine enkephalin
  • 26 Sep 2022 Discontinued - Phase-II for COVID-2019 infections (unspecified route)
  • 26 Sep 2022 Discontinued - Phase-II for Influenza A virus H1N1 subtype (Intranasal)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top